{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:54:18Z","timestamp":1790409258203,"version":"4.1.0"},"reference-count":62,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.clml.2025.10.004","type":"journal-article","created":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T03:07:15Z","timestamp":1759633635000},"page":"66-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["SOHO State of the Art Updates and Next Questions | Treatment of Myeloma Early Relapse: Non-CAR T Cell"],"prefix":"10.1016","volume":"26","author":[{"given":"Maria","family":"Gavriatopoulou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios","family":"Manganas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Ntanasis-Stathopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios-Athanasios","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.clml.2025.10.004_bib0001","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S1470-2045(20)30756-7","article-title":"Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.clml.2025.10.004_bib0002","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.70012","article-title":"Determinants of 15-year progression-free survival in multiple myeloma; real-world data from a single institution","volume":"100","author":"Dimopoulos","year":"2025","journal-title":"Am J Hematol"},{"issue":"19","key":"10.1016\/j.clml.2025.10.004_bib0003","doi-asserted-by":"crossref","first-page":"2904","DOI":"10.1182\/blood.2020008734","article-title":"How I treat relapsed multiple myeloma","volume":"139","author":"Kastritis","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2025.10.004_bib0004","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41408-022-00695-5","article-title":"Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: consensus recommendations of the NCI Multiple Myeloma Steering Committee","volume":"12","author":"Kumar","year":"2022","journal-title":"Blood Cancer J"},{"issue":"9","key":"10.1016\/j.clml.2025.10.004_bib0005","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","article-title":"EHA-EMN Evidence-based guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma","volume":"22","author":"Dimopoulos","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"10.1016\/j.clml.2025.10.004_bib0006","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1200\/JCO.22.00940","article-title":"Overall survival with daratumumab, lenalidomide, and dexamethasone in previously treated multiple myeloma (POLLUX): a randomized, open-label, phase III trial","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2025.10.004_bib0007","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1182\/bloodadvances.2023010579","article-title":"Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX","volume":"8","author":"Spencer","year":"2024","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.clml.2025.10.004_bib0008","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41408-023-00797-8","article-title":"Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized phase 3 study","volume":"13","author":"Martin","year":"2023","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.clml.2025.10.004_bib0009","doi-asserted-by":"crossref","first-page":"e741","DOI":"10.1016\/S2352-3026(24)00148-0","article-title":"Isatuximab plus carfilzomib-dexamethasone versus carfilzomib-dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trial","volume":"11","author":"Yong","year":"2024","journal-title":"Lancet Haematol"},{"issue":"5","key":"10.1016\/j.clml.2025.10.004_bib0010","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/ejh.13835","article-title":"Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis","volume":"109","author":"Spicka","year":"2022","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.clml.2025.10.004_bib0011","doi-asserted-by":"crossref","first-page":"e3258","DOI":"10.1002\/hon.3258","article-title":"Isatuximab in combination with carfilzomib and dexamethasone in 1q21+ patients with relapsed\/refractory multiple myeloma: long-term outcomes in the phase 3 IKEMA study","volume":"42","author":"Facon","year":"2024","journal-title":"Hematol Oncol"},{"issue":"6","key":"10.1016\/j.clml.2025.10.004_bib0012","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.3324\/haematol.2021.279229","article-title":"Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis","volume":"107","author":"Capra","year":"2022","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.clml.2025.10.004_bib0013","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(21)00579-9","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study","volume":"23","author":"Usmani","year":"2022","journal-title":"Lancet Oncol"},{"issue":"14","key":"10.1016\/j.clml.2025.10.004_bib0014","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/bloodadvances.2023010026","article-title":"Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study","volume":"7","author":"Usmani","year":"2023","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.clml.2025.10.004_bib0015","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa2403407","article-title":"DREAMM-8 Investigators. Belantamab mafodotin, pomalidomide, and dexamethasone in multiple myeloma","volume":"391","author":"Dimopoulos","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clml.2025.10.004_bib0016","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"ASPIRE investigators. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.clml.2025.10.004_bib0017","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"TOURMALINE-MM1 Study Group. Oral Ixazomib, Lenalidomide, and dexamethasone for Multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.clml.2025.10.004_bib0018","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1002\/cncr.31680","article-title":"Elotuzumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial","volume":"124","author":"Dimopoulos","year":"2018","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.clml.2025.10.004_bib0019","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1200\/JCO.2017.76.5032","article-title":"Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"36","author":"Siegel","year":"2018","journal-title":"J Clin Onco"},{"issue":"1","key":"10.1016\/j.clml.2025.10.004_bib0020","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13045-018-0583-7","volume":"11","author":"Dimopoulos","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"3","key":"10.1016\/j.clml.2025.10.004_bib0021","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/bjh.14549","article-title":"Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study","volume":"177","author":"Dimopoulos","year":"2017","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.clml.2025.10.004_bib0022","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/hon.2499","article-title":"Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: a subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials","volume":"36","author":"Mateos","year":"2018","journal-title":"Hematol Oncol"},{"issue":"22","key":"10.1016\/j.clml.2025.10.004_bib0023","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1200\/JCO.21.00972","article-title":"Final overall survival analysis of the TOURMALINE-MM1 Phase III trial of ixazomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"39","author":"Richardson","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clml.2025.10.004_bib0024","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.3324\/haematol.2017.170118","article-title":"Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed\/refractory multiple myeloma in TOURMALINE-MM1","volume":"102","author":"Mateos","year":"2017","journal-title":"Haematologica"},{"issue":"14","key":"10.1016\/j.clml.2025.10.004_bib0025","doi-asserted-by":"crossref","first-page":"935","DOI":"10.2217\/fon-2023-0604","article-title":"INSURE: a pooled analysis of ixazomib-lenalidomide-dexamethasone for relapsed\/refractory myeloma in routine practice","volume":"20","author":"Leleu","year":"2024","journal-title":"Future Oncol"},{"issue":"9","key":"10.1016\/j.clml.2025.10.004_bib0026","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1002\/ajh.27382","article-title":"Ixazomib plus daratumumab and dexamethasone: final analysis of a phase 2 study among patients with relapsed\/refractory multiple myeloma","volume":"99","author":"Delimpasi","year":"2024","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.clml.2025.10.004_bib0027","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/ajh.27206","article-title":"Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide-exposed patients after one prior line of therapy: final results of the phase 2 study DARIA","volume":"99","author":"Terpos","year":"2024","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.clml.2025.10.004_bib0028","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41408-020-00357-4","article-title":"Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study","volume":"10","author":"Dimopoulos","year":"2020","journal-title":"Blood Cancer J"},{"issue":"7","key":"10.1016\/j.clml.2025.10.004_bib0029","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"ELOQUENT-2 Investigators. Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clml.2025.10.004_bib0030","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa2405090","article-title":"DREAMM-7 Investigators. Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma","volume":"391","author":"Hungria","year":"2024","journal-title":"N Engl J Med"},{"issue":"10262","key":"10.1016\/j.clml.2025.10.004_bib0031","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","article-title":"Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial","volume":"396","author":"Grosicki","year":"2020","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.clml.2025.10.004_bib0032","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/ejh.14223","article-title":"Impact of prior treatment on selinexor, bortezomib, dexamethasone outcomes in patients with relapsed\/refractory multiple myeloma: extended follow-up subgroup analysis of the BOSTON trial","volume":"113","author":"Mateos","year":"2024","journal-title":"Eur J Haematol"},{"issue":"3","key":"10.1016\/j.clml.2025.10.004_bib0033","doi-asserted-by":"crossref","first-page":"E83","DOI":"10.1002\/ajh.26434","article-title":"Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: subgroup analysis from the BOSTON study","volume":"97","author":"Delimpasi","year":"2022","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.clml.2025.10.004_bib0034","doi-asserted-by":"crossref","first-page":"E383","DOI":"10.1002\/ajh.26282","article-title":"Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone","volume":"96","author":"Sanchez","year":"2021","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.clml.2025.10.004_bib0035","doi-asserted-by":"crossref","first-page":"e813","DOI":"10.1016\/S2352-3026(23)00218-1","article-title":"Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial","volume":"10","author":"Dimopoulos","year":"2023","journal-title":"Lancet Haematol"},{"issue":"6","key":"10.1016\/j.clml.2025.10.004_bib0036","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","article-title":"OPTIMISMM Trial Investigators. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial","volume":"20","author":"Richardson","year":"2019","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.clml.2025.10.004_bib0037","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1200\/JCO.21.02734","article-title":"Overall survival with daratumumab, bortezomib, and dexamethasone in previously treated multiple myeloma (CASTOR): a randomized, open-label, phase III trial","volume":"41","author":"Sonneveld","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2025.10.004_bib0038","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1182\/blood.2024025746","article-title":"Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study","volume":"145","author":"Badros","year":"2025","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2025.10.004_bib0039","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.10.004_bib0040","unstructured":"Pfizer. MagnetisMM-5: study of elranatamab (PF-06863135) monotherapy and elranatamab + daratumumab versus daratumumab + pomalidomide + dexamethasone in participants with relapsed\/refractory multiple myeloma (MAGNETISMM-5). https:\/\/clinicaltrials.gov\/study\/NCT05020236."},{"key":"10.1016\/j.clml.2025.10.004_bib0041","unstructured":"Pfizer. MagnetisMM-32: a Study to Learn about the Study Medicine Called Elranatamab in People with Multiple Myeloma (MM) That Has Come Back after Taking Other Treatments (Including Prior Treatment with an Anti-CD38 Antibody and Lenalidomide). https:\/\/clinicaltrials.gov\/study\/NCT06152575."},{"key":"10.1016\/j.clml.2025.10.004_bib0042","unstructured":"Janssen Research. Development, LLC A study comparing Teclistamab monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in participants with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide. https:\/\/clinicaltrials.gov\/study\/NCT05572515."},{"key":"10.1016\/j.clml.2025.10.004_bib0043","unstructured":"Regeneron Pharmaceuticals. A Trial to Learn HowWell LinvoseltamabWorks Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants with Relapsed\/Refractory Multiple Myeloma (LINKER-MM3). https:\/\/clinicaltrials.gov\/study\/NCT05730036."},{"key":"10.1016\/j.clml.2025.10.004_bib0044","unstructured":"Janssen Research. Development, LLC A study comparing Talquetamab in combination with pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide. https:\/\/clinicaltrials.gov\/study\/NCT06208150."},{"issue":"24","key":"10.1016\/j.clml.2025.10.004_bib0045","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clml.2025.10.004_bib0046","unstructured":"Nanjing IASO Biotechnology Co., Ltd. A phase III study of Eque-cel in subjects with len-refractory RRMM (FUMANBA-03) (FUMANBA-03). https:\/\/clinicaltrials.gov\/study\/NCT06464991."},{"key":"10.1016\/j.clml.2025.10.004_bib0047","unstructured":"Kite, A Gilead Company. A study comparing Anitocabtagene Autoleucel to standard of care therapy in participants with relapsed\/refractory multiple myeloma (iMMagine-3). https:\/\/clinicaltrials.gov\/study\/NCT06413498."},{"key":"10.1016\/j.clml.2025.10.004_bib0048","unstructured":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company. A phase 3, randomized, open-label, Multicenter Study to Compare the Efficacy and Safety of BMS-986393, a GPRC5D-directed CAR-T Cell Therapy, versus Standard Regimens in Adult Participants with Relapsed or Refractory and Lenalidomide-refractory Multiple Myeloma. https:\/\/clinicaltrials.gov\/study\/NCT06615479."},{"key":"10.1016\/j.clml.2025.10.004_bib0049","unstructured":"Celgene. A study to evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) (SUCCESSOR-1). https:\/\/clinicaltrials.gov\/study\/NCT05519085."},{"key":"10.1016\/j.clml.2025.10.004_bib0050","unstructured":"Bristol-Myers Squibb. A study to evaluate mezigdomide in combination with Carfilzomib and Dexamethasone (MeziKD) versus Carfilzomib and Dexamethasone (Kd) in participants with relapsed or refractory multiple myeloma (SUCCESSOR-2) (SUCCESSOR-2). https:\/\/clinicaltrials.gov\/study\/NCT05552976."},{"key":"10.1016\/j.clml.2025.10.004_bib0051","unstructured":"Celgene. Open-label study comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM) (EXCALIBER-RRMM). https:\/\/clinicaltrials.gov\/study\/NCT04975997."},{"key":"10.1016\/j.clml.2025.10.004_bib0052","unstructured":"Stichting European Myeloma Network. A phase 3 randomized, open-label trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in patients with relapsed or refractory multiple myeloma (RRMM). https:\/\/clinicaltrials.gov\/study\/NCT05028348."},{"key":"10.1016\/j.clml.2025.10.004_bib0053","unstructured":"Antengene Corporation, A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) versus Bortezomib and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) (BENCH). https:\/\/clinicaltrials.gov\/study\/NCT04939142."},{"issue":"3","key":"10.1016\/j.clml.2025.10.004_bib0054","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41375-024-02482-6","article-title":"International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma","volume":"39","author":"Costa","year":"2025","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.clml.2025.10.004_bib0055","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1038\/s41375-025-02677-5","article-title":"The impact of high-risk cytogenetics on treatment efficacy and outcomes of patients with relapsed\/refractory multiple myeloma: a systematic review and meta-analysis of randomized controlled trials","volume":"39","author":"Ntanasis-Stathopoulos","year":"2025","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.clml.2025.10.004_bib0056","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s12288-025-02008-9","article-title":"Approaches to managing relapsed myeloma: switching drug class or retreatment with same drug class?","volume":"41","author":"Vijjhalwar","year":"2025","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"1","key":"10.1016\/j.clml.2025.10.004_bib0057","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1182\/hematology.2023000444","article-title":"Considerations for next therapy after anti-CD38 monoclonal antibodies used as first line","volume":"2023","author":"Hartley-Brown","year":"2023","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2025.10.004_bib0058","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-025-02654-y","article-title":"Current risk stratification and staging of multiple myeloma and related clonal plasma cell disorders","author":"Zanwar","year":"2025","journal-title":"Leukemia"},{"issue":"14","key":"10.1016\/j.clml.2025.10.004_bib0059","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.3390\/cancers15143687","article-title":"Minimal residual disease in multiple myeloma: past, present, and future","volume":"15","author":"Medina-Herrera","year":"2023","journal-title":"Cancers (Basel)."},{"issue":"6","key":"10.1016\/j.clml.2025.10.004_bib0060","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s12185-022-03353-5","article-title":"Multiple myeloma with high-risk cytogenetics and its treatment approach","volume":"115","author":"Hanamura","year":"2022","journal-title":"Int J Hematol"},{"issue":"3","key":"10.1016\/j.clml.2025.10.004_bib0061","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/ajh.27582","article-title":"Evaluating minimal residual disease negativity as a surrogate endpoint for treatment efficacy in multiple myeloma: a meta-analysis of randomized controlled trials","volume":"100","author":"Ntanasis-Stathopoulos","year":"2025","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.clml.2025.10.004_bib0062","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/s13045-021-01162-7","article-title":"Prognostic and predictive biomarker developments in multiple myeloma","volume":"14","author":"Wallington-Beddoe","year":"2021","journal-title":"J Hematol Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042302?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042302?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T15:18:38Z","timestamp":1770650318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025042302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2152265025042302"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.10.004","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SOHO State of the Art Updates and Next Questions | Treatment of Myeloma Early Relapse: Non-CAR T Cell","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}